The U.S. Food and Drug Administration has allowed Medical Microinstruments, known as MMI, to expand enrollment in an early feasibility study of robotic microsurgery for people with Alzheimer's disease.

The FDA approved a supplement to the investigational device exemption for the REMIND study after reviewing 30-day safety data from the first patients treated. The initial cohort included up to five participants. Enrollment can now expand to the study's planned population of 15.

What the study is testing

REMIND stands for Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease. The prospective early feasibility study is evaluating the safety and feasibility of using MMI's Symani Surgical System to perform microsurgical techniques in the deep cervical lymph-node region.

Participants have mild to moderate Alzheimer's disease and confirmed lymphatic abnormalities. Researchers are studying whether microsurgery can re-establish lymphatic drainage pathways that may be involved in clearing substances such as amyloid-beta and phosphorylated tau from the brain.

The ClinicalTrials.gov record identifies device-related serious adverse events at 30 days as a primary outcome. The study is therefore primarily an evaluation of safety and procedural feasibility, not proof that the procedure improves cognition or changes the course of Alzheimer's disease.

Why the expansion matters

The enrollment expansion allows researchers to evaluate the procedure in a larger, although still small, patient group. Data from the study may inform later research and the possible design of a larger pivotal trial.

The development also extends surgical robotics into an unusual area of neurodegenerative-disease research. Symani is designed for microsurgical work involving very small structures, including blood and lymphatic vessels. The system filters tremor and translates a surgeon's movements into smaller movements by robotic instruments.

What the FDA decision does not establish

Approval of the investigational device exemption supplement is not FDA approval of the procedure as an Alzheimer's treatment. MMI states that the safety and effectiveness of Symani for lymphatic reconstruction in brain disease have not been established and that the system remains investigational for this use.

The next evidence from REMIND will concern whether the procedure can be performed with an acceptable safety profile and whether the proposed microsurgical approach is feasible. Claims about clinical benefit, neurotoxin clearance, cognition, or disease progression will require substantially more evidence.